Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AP Antivirals for treatment of HCV infections
J05AP08 Sofosbuvir
D10366 Sofosbuvir (JAN/USAN/INN) <US>
USP drug classification [BR:br08302]
Antivirals
Anti-hepatitis C (HCV) Agents
Sofosbuvir
D10366 Sofosbuvir (JAN/USAN/INN)
Drug groups [BR:br08330]
Antiviral
DG03198 Anti-HCV agent
DG02000 HCV NS5B polymerase inhibitor
D10366 Sofosbuvir
Transporter substrate
DG01665 ABCB1 substrate
D10366 Sofosbuvir
DG01913 ABCG2 substrate
D10366 Sofosbuvir
Drug classes [BR:br08332]
Antiviral
DG03198 Anti-HCV agent
D10366 Sofosbuvir
Antimicrobials [BR:br08307]
Antivirals
Genome replication inhibitor
HCV NS5A/NS5B inhibitor
D10366 Sofosbuvir (JAN/USAN/INN) <US>
Antimicrobials abbreviations [BR:br08327]
Antivirals
Genome replication inhibitor
HCV NS5A/NS5B inhibitor
D10366 Sofosbuvir (JAN/USAN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10366
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10366
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10366
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10366
Drug metabolizing enzymes and transporters [br08309.html]
Drug transporters
D10366
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D10366